PTC Therapeutics マネジメント

マネジメント基準チェック /24

PTC Therapeuticsの CEO はMatt Kleinで、 Mar2023年に任命され、の在任期間は 1.67年です。の年間総報酬は$ 8.94Mで、 8.4%給与と91.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.068%を直接所有しており、その価値は$ 2.27M 。経営陣と取締役会の平均在任期間はそれぞれ5.7年と9.4年です。

主要情報

Matt Klein

最高経営責任者

US$8.9m

報酬総額

CEO給与比率	8.4%
CEO在任期間	1.7yrs
CEOの所有権	0.07%
経営陣の平均在職期間	5.7yrs
取締役会の平均在任期間	9.4yrs

経営陣の近況

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

CEO報酬分析

PTC Therapeutics の収益と比較して、Matt Klein の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$453m
Jun 30 2024	n/a	n/a	-US$480m
Mar 31 2024	n/a	n/a	-US$579m
Dec 31 2023	US$9m	US$747k	-US$627m
Sep 30 2023	n/a	n/a	-US$642m
Jun 30 2023	n/a	n/a	-US$618m
Mar 31 2023	n/a	n/a	-US$571m
Dec 31 2022	US$5m	US$598k	-US$559m

報酬と市場: Mattの総報酬 ($USD 8.94M ) は、 US市場 ($USD 6.56M ) の同規模の企業の平均を上回っています。

報酬と収益: Mattの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Matt Klein (52 yo)

1.7yrs

在職期間

US$8,937,025

報酬

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% $ 2.3m
Stuart Peltz	Co-Founder	26.8yrs	US$5.66m	データなし
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% $ 533.8k
Pierre Gravier	Chief Financial Officer	1.3yrs	US$3.01m	0.015% $ 515.8k
Mark Boulding	Executive VP & Chief Legal Officer	12.7yrs	US$2.19m	0.063% $ 2.1m
Eric Pauwels	Chief Business Officer	9.6yrs	US$2.41m	0.026% $ 852.9k
Lee Golden	Executive VP & Chief Medical Officer	4.5yrs	US$2.39m	0.019% $ 642.8k
Christine Utter	Senior VP	5.4yrs	US$1.70m	0.022% $ 737.2k
Neil Almstead	Chief Technical Operations Officer	5.9yrs	US$2.67m	0.054% $ 1.8m
Linda Carter	Senior VP & Chief Information Officer	less than a year	データなし	データなし
Alex Kane	Investor Relations Officer	no data	データなし	データなし
Jane Baj	Vice President of Corporate Communications	no data	データなし	データなし

5.7yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: PTCTの経営陣は経験豊富で経験豊富です（平均在職期間は5.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% $ 2.3m
Stuart Peltz	Co-Founder	1.7yrs	US$5.66m	データなし
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% $ 533.8k
Michael Schmertzler	Independent Chairman of the Board	23.3yrs	US$816.96k	1.95% $ 64.9m
David Southwell	Independent Director	18.9yrs	US$438.98k	0.014% $ 453.8k
Eric Jacobsen	Member of the Scientific Advisory Board	no data	データなし	データなし
Emma Reeve	Independent Director	5.9yrs	US$441.98k	0.0093% $ 311.4k
Joseph Puglisi	Member of Scientific Advisory Board	21yrs	データなし	データなし
Glenn Steele	Independent Director	9.4yrs	US$426.98k	0.014% $ 453.8k
Marvin Wickens	Member of Scientific Advisory Board	no data	データなし	データなし
Robert Schneider	Member of Scientific Advisory Board	no data	データなし	データなし
Stephanie Okey	Independent Director	5.9yrs	US$421.98k	0.0076% $ 253.7k

9.4yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: PTCTの取締役会は経験豊富であると考えられます ( 9.4年の平均在任期間)。

PTC Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

CEO, COO & Director recently sold US$63k worth of stock

Recent updates

Price target increased by 8.4% to US$45.00

PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy

New minor risk - Profitability

New minor risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission

PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

New minor risk - Share price stability

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

マネジメント基準チェック /24